Replies to post #239196 on Innovation Pharmaceuticals Inc (IPIX)

[DesireToLearn]

Let's say it's 13 people vs 6 placebo. Keep in mind subjects had mild psoriasis, so not surprising placebo is higher....Should be lower in P2B. On flip side, based on stratified data since P2B has moderate / severe psoriasis the # of people with success should be higher. So spread widens.

[georgejjl]

The FACTS don't support your posts.

Below are the FACTS:

For apremilast (Otezla) only 9 subjects out of 30 (30%) achieved PASI 75 in the CC-10004-PSOR Phase 2 trial.

https://media.celgene.com/content/uploads/CC-10004-PSOR-004-Synopsis-Redacted.pdf

For Prurisol Phase 2 trial"

For the 200 mg/day (100 mg BID), 7 subjects out of 27 (25.9%)subjects achieved at least a 2 point reduction IGA for the ITT (Intent To Treat) population.

For the 200 mg/day (100 mg BID), 7 subjects out of 20 (35%)subjects achieved at least a 2 point reduction IGA for the PP (Per Protocol) population.

Among patients with the severest form of psoriasis in study, those having a baseline
IGA score of 3 (“moderate”), the primary endpoint was met in 46% of patients who
received 200 mg per day.

https://static1.squarespace.com/static/5715352e20c647639137f992/t/583ddc8303596e5fc7e8bf06/1480449160455/Cellceutix_Corporate_Slide+Deck_DERMATOLOGY_November+2016+Website+Vers.pdf

Good luck and GOD bless,

George